HALCION Drug Patent Profile

When do Halcion patents expire, and when can generic versions of Halcion launch?

Halcion is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in HALCION is triazolam. There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the triazolam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Halcion

A generic version of HALCION was approved as triazolam by NOVAST LABS on October 20^th, 2020.

Summary for HALCION

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for HALCION

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-003	Apr 26, 1985	AB	RX	Yes	No
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-001	Nov 15, 1982	AB	RX	Yes	Yes
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-002	Nov 15, 1982		DISCN	No	No

International Patents for HALCION

See the table below for patents covering HALCION around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	80541
South Africa	7201489
Spain	376689
United Kingdom	1291631
Germany	2012190
Sweden	387641	ANALOGIFORFARANDE FOR FRAMSTELLNING AV S-TRIAXOLO(4,3-A)(1,4)BENSODIAZEPINER
Guatemala	197223779	COMPOSICIONES DE 8-CLORO-1-METIL-6-(O-CLOROFENIL)-4H-S-TRIA-ZOL [4,3-A] [1,4] BENZODIAZEPINA Y METODO DE TRATAMIENTO.

Investment Scenario and Fundamentals Analysis for Halcion (Triazolam)

Last updated: March 1, 2026

What is the current market position of Halcion?

Halcion (triazolam) is a benzodiazepine primarily used for short-term treatment of insomnia. Marketed by pharmaceutical companies mainly outside the US, its sales have declined due to safety concerns and regulatory restrictions. The global benzodiazepine market was valued at approximately $1.7 billion in 2021, with triazolam representing a small segment, estimated under $100 million annually.

Key market dynamics:

• Declining prescriptions owing to safety issues, including dependence and withdrawal risks.
• Regulatory restrictions in the US; FDA withdrew approval in 1998.
• Prescribed mainly in Europe and Asia, with growing interest in alternative sleep aids.

What are the underlying R&D and patent fundamentals?

Patent status:

• The original patents for triazolam expired decades ago.
• No new patents filed on the molecule or formulations in recent years.
• Current formulations are off-patent generics, limiting exclusivity and investment returns.

Research and development activity:

• Minimal R&D focused on triazolam itself.
• Sparse pipeline interest for new formulations or safety profile improvements.
• Competing drugs include zolpidem, eszopiclone, and suvorexant, with more favorable safety profiles.

How do safety and regulatory issues impact investment?

Safety concerns:

• Risks of cognitive impairment, dependence, and withdrawal.
• Adverse effects led to public health warnings and reduced prescribing.
• US FDA issued black box warnings in the 1990s.

Regulatory environment:

• US market largely inaccessible; regulatory restrictions inhibit growth.
• Europe and Asia have more permissive regulations but limited market growth.
• The risk of future regulatory actions remains, affecting profitability.

What are the financial outlooks?

Given the market decline, revenue projections are low:

• Global sales estimated at $80–$100 million annually.
• No recent patent protection or exclusivity.
• Margins are slim due to generic competition and regulatory costs.
• Limited pipeline or innovative development plans.

What alternatives exist for investors?

• Shift focus toward drugs with growth potential and newer mechanisms.
• Monitor for regulatory shifts or new formulations addressing safety.
• Consider off-label prescribing patterns and potential niche applications.

Key financial metrics:

Metric	Value	Comment
Market size	<$100 million	Small segment within benzodiazepines
Patent expiration	2000s	Limited exclusivity, high generic competition
R&D activity	Sparse	No recent innovation pipelines
Revenue trend	Declining	Due to safety concerns and loss of patent exclusivity
Regulatory risk	High	Potential for future restrictions

Key Takeaways

• Halcion's market has contracted due to safety issues and patent expiration.
• Limited R&D activity and absence of new formulations reduce future growth prospects.
• Regulatory restrictions in key markets constrain sales; Europe and Asia present limited opportunities.
• Investment risk remains high owing to safety concerns, generic competition, and regulatory uncertainties.

FAQs

1. Can new formulations revive Halcion's market?
Existing formulations are off-patent; developing new formulations faces regulatory hurdles and limited patient benefits, reducing investment appeal.

2. Is there potential for reformulation to improve safety?
Research into safer benzodiazepine derivatives exists but has not targeted triazolam specifically; ongoing safety issues limit reformulation prospects.

3. How does regulatory risk affect future sales?
Increased restrictions and warnings can further curtail prescribing, reducing sales regardless of reformulation efforts.

4. Are there niche markets for Halcion?
Use in specific clinical scenarios is limited; off-label applications are minimal and unlikely to boost market size significantly.

5. What are alternatives for investors interested in sleep aids?
Focus on drugs with established safety profiles and growth potential, such as dual orexin receptor antagonists or melatonin receptor agonists.

---

References

[1] Markets and Markets. Benzodiazepine Market 2022.
[2] U.S. Food and Drug Administration. Black box warning on benzodiazepines.
[3] GlobalData. Sleep aids market analysis 2021.
[4] European Medicines Agency. Regulatory status of benzodiazepines.
[5] Statista. Prescription trends for sleep medications 2022.